# Accuracy of the Anti-SARS-VoV-2 Rapid Test Kit

All testing was compared to RT-PCR tests performed from naso- or oropharyngeal swabs specimens.

Table 8: SARS-CoV-2 **IgM** Positive results of three disease periods from symptom onset

| Disease period (days) | Samples No. of PCR positive | No. of positive results by Autobio | Clinical Sensitivity | 95%CI |
|---|---|---|---|---|
| ≤7 | 51 | 19 | 37.25% | 23.99%~50.52% |
| 8-14 | 52 | 38 | 73.08% | 61.02%~85.13% |
| ≥15 | 302 | 289 | 95.70% | 93.41%~97.98% |

Table 9: SARS-CoV-2 **IgG** Positive results of three disease periods from symptom onset

| Disease period (days) | Samples No. of PCR positive | No. of positive results by Autobio | Clinical Sensitivity | 95%CI |
|---|---|---|---|---|
| ≤7 | 51 | 16 | 31.37% | 18.64%~44.11% |
| 8-14 | 52 | 34 | 65.38% | 52.45%~78.32% |
| ≥15 | 302 | 299 | 99.01% | 97.89%~100.13% |

Table 6: Results of **IgM** Clinical Sensitivity and Specificity – for all time periods from symptom onset

| Evaluation reagent | | PCR | | Total |
|---|---|---|---|---|
| | | Positive | Negative | |
| Autobio | Positive | 346 | 1 | 347 |
| | Negative | 59 | 311 | 370 |
| Total | | 405 | 312 | 717 |
| **IgM** Clinical Sensitivity | | 85.43% (95%CI：82.00%-88.87%) | | |
| **IgM** Clinical Specificity | | 99.68% (95%CI：99.05%-100.31%) | | |

Table 7: Results of **IgG** Clinical Sensitivity and Specificity – for all time periods from symptom onset

| Evaluation reagent | | PCR | | Total |
|---|---|---|---|---|
| | | Positive | Negative | |
| Autobio | Positive | 349 | 2 | 351 |
| | Negative | 56 | 310 | 366 |
| Total | | 405 | 312 | 717 |
| **IgG** Clinical Sensitivity | | 86.17% (95%CI：82.81%-89.53%) | | |
| **IgG** Clinical Specificity | | 99.36% (95%CI：98.47%-100.24%) | | |